Poster presentations: Clinical: Therapy and Observation 2022

P533 Predictors of sustained remission after infliximab de-escalation in patients with inflammatory bowel diseases

P534 Effectiveness and safety of Adalimumab switch from originator to biosimilar in patients with inflammatory bowel disease in clinical remission

P535 Association of anti-Infliximab antibodies and HLADQA1*05 variant in ulcerative colitis : a retrospective single centre study

P536 Comparison of outcomes of infliximab biosimilar CT-P13 with infliximab originator in patients with inflammatory bowel disease

P537 Steroid use in patients with immune checkpoint inhibitor colitis

P538 Implementation of Kono-S anastomosis as a new standard of surgical care

P539 COVID-19 is Associated with Long-term Elevated Fecal Calprotectin Levels in Patients with Crohn's Disease but not in Ulcerative Colitis.

P540 Longitudinal Dynamics of Gut Microbiome and Metabolome After Biological Therapy in Inflammatory Bowel Diseases

P541 Effectiveness, safety and durability of vedolizumab in active moderate-severe Crohn's Disease

P542 Topical tacrolimus versus systemic biological therapy for refractory ulcerative proctitis: a retrospective cohort study

P543 Point-of-care testing in therapeutic drug monitoring of infliximab

P544 Patients with moderate to severe Crohn’s disease with and without prior biologic failure demonstrated improved clinical outcomes with risankizumab: Results from phase 3 induction and maintenance trials

P545 Safety of ustekinumab in pregnant patients with inflammatory bowel disease and in their offspring: results from the DUMBO registry of GETECCU

P546 Minimal risk of lymphoma despite long term use of azathioprine in patients with Inflammatory Bowel Disease: a longitudinal cohort analysis from Northern India.

P547 Early modification of inflammatory burden through treatment with vedolizumab or adalimumab is predictive of long-term treatment success in patients with Ulcerative Colitis from the VARSITY Study

P548 External validation and consistency in time of patient segmentation based on disease acceptance and perceived control in Inflammatory Bowel Disease

P549 Oxidative stress and antioxidant capacity biomarkers in adults and children with IBD: current update from OxIBDiet trial

P550 Management of immunomodulators and biologic agents in pregnant patients with inflammatory bowel: results from the DUMBO registry of GETECCU

P551 Safety and effectiveness of vedolizumab for the treatment of paediatric patients with Inflammatory Bowel Diseases

P552 Higher Serum Ustekinumab Levels Correlate With Higher Rates Of Steroid-Free Deep Remission And Endoscopic Healing In Patients With Inflammatory Bowel Diseases

P554 Vedolizumab Associated quality of Life and inflammatory bowel disease control Upon Entering a subcutaneous switching program (VALUE) – Results from a multi-centre UK study

P555 Ustekinumab tissue and serum levels in patients with Crohn’s disease are closely correlated though not consistently associated with objective response after induction.

P556 The effect of multiple doses of upadacitinib 45 mg on the pharmacokinetics of cytochrome P450 substrates in healthy adult subjects

P557 Robotic surgery significantly improves outcomes for patients with inflammatory bowel disease

P558 Should we introduce early a new biological agent in patients with Inflammatory Bowel Disease after anti-TNF discontinuation due to severe anti-TNF-induced skin lesions? A multicenter cohort study.

P559 Cannabis Improves Sleep Quality in Patients with Inflammatory Bowel Diseases in a Prospective Observational Study

P560 Application of a clinical decision support tool for predicting outcomes with vedolizumab therapy in patients with inflammatory bowel disease: A KASID multicenter study

P561 Clinical utility of therapeutic drug monitoring of adalimumab using a point of care test

P562 A Phase 1 Study Evaluating the Effect of Coadministration of Etrasimod on the Pharmacokinetics and Pharmacodynamics of a Monophasic Oral Contraceptive in Healthy Female Volunteers

P563 Association between smoking status and the efficacy and safety of tofacitinib in patients with Ulcerative Colitis: Data from the tofacitinib clinical programme

P564 A qualitative exploration of acceptability of long-term use of oral nutritional supplement drinks as partial enteral nutrition in adolescent and adult Crohn's Disease

P565 COVID-19 vaccination satisfaction and hesitancy in patients with inflammatory bowel disease: “inside referral center” survey

P566 Humoral immune response to mRNA COVID-19 vaccine in Puerto Ricans with IBD does not differ between class of biologics

P567 Safety analysis of tofacitinib in ulcerative colitis: Real-world outcomes from a three-year UK observational cohort study

P568 Impact of Biologics and Small Molecules for Inflammatory Bowel Disease on COVID-19 Related Hospitalization: A Systematic Review and Meta-analysis

P569 Fecal Microbiome Transplantation for Recurrent C. difficile Colitis: Treatment Efficacy, Short and Long-term Follow-up Results from Consecutive Case Series

P570 Prevalence and risk factors for intestinal resection in patients with Crohn’s disease in a Greek referral center

P571 The Nordic diet as a tool to improve the activity of disease and psycho-emotional wellbeing in patients with mild and moderate Ulcerative Colitis – the pilot study.

P572 Therapy optimisation and intravenous ferric carboxymaltose in active or inactive IBD with iron deficiency: it's time to make iron deficiency part of tight monitoring to reach T2T? – preliminary results of a prospective study

P573 The safety profile of upadacitinib maintenance therapy in ulcerative colitis in the Phase 3 U-ACHIEVE study is consistent with that in approved indications

P574 Population pharmacokinetic and exposure-response analyses for efficacy and safety of risankizumab in subjects with active Crohn‘s disease

P575 Safety and efficacy of autologous haematopoietic stem cell transplantation for refractory Crohn’s disease after cyclophosphamide-free mobilisation: Preliminary Results

P576 Real-world effectiveness and safety of risankizumab in patients with moderate-to-severe multi-refractory Crohn’s disease: a Belgian multi-centric cohort study

P577 Mucosal eosinophil abundance in non-inflamed colonic tissue predict response to vedolizumab induction therapy in inflammatory bowel disease

P578 Non-medical switch between adalimumab biosimilars and from the originator adalimumab to biosimilars in inflammatory bowel disease patients – a multicentre study on efficacy and drug sustainability

P579 Rates, predictive factors and effectiveness of ustekinumab intensification to 4- or 6-weekly intervals in Crohns’s disease

P580 Early intestinal ultrasound assessment predicts endoscopic response and remission on anti-TNF treatment in Crohn’s Disease – a prospective longitudinal cohort study

P581 Transmural remission improves clinical outcomes up to 5 years in patients with Crohn’s Disease

P582 Association between serum ustekinumab concentrations and endoscopic disease activity in Crohn’s disease

P583 Ustekinumab during pregnancy in patients with inflammatory bowel disease: a prospective multicenter cohort study

P584 Systematic Review and Meta-analysis Evaluating the Real-World Effectiveness and Safety of Ustekinumab in Crohn’s Disease

P585 Examining faecal incontinence and its impact on health-related quality of life in patients with Crohn’s perianal fistulas: results from a multi-country burden of illness study

P586 Surgical recurrence in Crohn’s Disease: Can we prevent it?

P587 Disease severity in the INFLAMMATORY BOWEL DISEASES: Do patients and physicians agree?

P588 T cell response to SARS-CoV-2 mRNA vaccines by an interferon-gamma release immunoassay in patients with Inflammatory Bowel disease receiving anti-TNF and thiopurine treatment

P589 Total thiopurine exposure and impact on the development of keratinocyte carcinomas in Inflammatory Bowel Disease patients; a case control study

P590 Thromboprophylaxis use in paediatric inflammatory bowel disease: an international RAND appropriateness panel

P591 Biological therapies and small molecules show to be efficacious in patients with moderate-to-severe ulcerative proctitis.

P592 Effectiveness and safety of thioguanine in thiopurine-naïve Inflammatory Bowel Disease patients

P593 Biologicals and small molecule combotherapies: promising experience in refractory IBD patients

P594 Vedolizumab dose intensification does not always improve treatment persistence.

P595 Validation of a predictive algorithm for thiopurine induced hepatotoxicity in IBD patients

P596 Adalimumab use in Paediatric Inflammatory Bowel Disease: A single centre real-life experience

P597 Bone mineral density in patients after total proctocolectomy and pouch surgery due to Ulcerative Colitis have low bone mineral density, and low performance of DXA scans- a cross sectional study

P598 Indicators for inadequate response among patients with Ulcerative Colitis treated with advanced therapies in German clinical practice

P599 Azathioprine in the prevention of anti-infliximab antibody formation: A pilot dose-finding study

P600 Serologic response to COVID-19 vaccines in IBD patients: a prospective study

P601 Real World Evidence on the comparative effectiveness of Ustekinumab vs anti-TNF in Crohn’s disease with Propensity Score adjustment: maintenance phase results from the prospective observational RUN-CD study

P602 Tofacitinib treatment prevents post-operative recurrence of Crohn’s Disease modeled by ileocecal resection in HLA-B27 transgenic rats.

P603 INSPIRE: 6-month interim analysis from an observational post-marketing registry on the effectiveness and safety of darvadstrocel in patients with Crohn’s disease and complex perianal fistulas

P604 Infection Risk in Elderly Patients with Inflammatory Bowel Disease under anti-TNF, ustekinumab or vedolizumab biologic therapies: A Prospective Multicenter observational One-Year follow-up comparative study.

P605 Immunogenicity and safety of standard and third dose SARS-CoV-2 vaccination in patients with immune-mediated inflammatory diseases; a prospective cohort study

P606 Use of TNF-α-antagonists and systemic steroids is associated with attenuated immunogenicity against SARS-CoV-2 in fully vaccinated patients with Inflammatory Bowel Disease

P607 Efficacy and safety of tofacitinib in Ulcerative Colitis patients with extraintestinal manifestations in OCTAVE Open

P608 Systematic review: The impact and importance of body composition in Inflammatory Bowel Disease

P609 Significant variations in practice in managing mild-Crohn’s disease: results from the 2021 Y-ECCO-ClinCom survey

P610 Safety of COVID-19 vaccine in patients with Inflammatory Bowel Disease: preliminary data of a national study (ESCAPE-IBD)

P611 Serological biomarkers of type VI and XXII collagen formation predict and monitor infliximab treatment response in patients with Crohn’s disease

P612 Mirikizumab Pharmacokinetics and Exposure - Efficacy Relationships in Patients with Ulcerative Colitis

P613 Comparative objective effectiveness of vedolizumab and ustekinumab in a real-life cohort of active Crohn’s disease patients failure to TNF inhibitors.

P614 Proactive infliximab is superior to either conventional infliximab and vedolizumab in Inflammatory Bowel Disease

P615 Improving IBD monitoring by understanding preanalytical faecal calprotectin variability

P616 Safety of COVID-19 vaccines in patients with IBD

P617 Switching from an intensified regimen of infliximab to a subcutaneous standard dose in adults with Inflammatory Bowel Disease: our experience in a tertiary hospital.

P618 Pre-operative oral enteral nutritional optimisation for Crohn’s disease: A retrospective UK tertiary IBD centre cohort study

P619 Patterns of Anti-TNF Prescribing & Therapy Outcome in a Large Multicentre Cohort of Inflammatory Bowel Disease Patients

P620 Differences in illness perceptions of Inflammatory Bowel Disease (IBD) between Healthcare Practitioners (HCPs) and patients in a UK tertiary IBD centre.

P621 Secure Electronic Document Signing Uptake in Biologic Prescribing for Immune Mediate Diseases

P622 Comparison of long-term outcomes of infliximab and adalimumab in biologic-naïve patients with ulcerative colitis

P623 The effectiveness and tolerability of Crohn’s disease exclusion diet in adult Crohn’s disease patients: a retrospective study

P624 Long-term effectiveness of anti-TNF therapy in pediatric-onset inflammatory bowel diseases: a population-based study

P625 Predictors of pancreatitis among patients with inflammatory bowel disease (IBD) treated with vedolizumab (VDZ): Observation from a large global safety database

P626 Anti-TNF monotherapy is associated with an adverse clinical outcome in female Inflammatory Bowel Disease patients who stop Anti-TNF treatment during the third trimester of pregnancy.

P627 Variables associated with evolution to moderate to severe Crohn's disease at two reference centers in Salvador, Bahia, Brazil

<< < 1 [2]

ECCO'25 Abstracts

ECCO'24 Abstracts

Poster presentations: Clinical: Therapy and Observation 2022